Martin Auster
Stock Analyst at UBS
(1.45)
# 2,698
Out of 4,667 analysts
47
Total ratings
53.57%
Success rate
7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $62.56 | +91.82% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $46.40 | +126.29% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $2.99 | +769.57% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $4.96 | +2,319.35% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $5.81 | +5,063.51% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $11.31 | +412.82% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $364.33 | -46.20% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $1.21 | +7,999.17% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $72.67 | -17.43% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $27.86 | +133.31% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $110.86 | -34.15% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $2.49 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $5.70 | +1,268.42% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.41 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $15.91 | +170.27% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $43.65 | -22.11% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.12 | +60.06% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $20.31 | -21.22% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $62.56
Upside: +91.82%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $46.40
Upside: +126.29%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $2.99
Upside: +769.57%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $4.96
Upside: +2,319.35%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $5.81
Upside: +5,063.51%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $11.31
Upside: +412.82%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $364.33
Upside: -46.20%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.21
Upside: +7,999.17%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $72.67
Upside: -17.43%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $27.86
Upside: +133.31%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $110.86
Upside: -34.15%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $2.49
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $5.70
Upside: +1,268.42%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.41
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $15.91
Upside: +170.27%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $43.65
Upside: -22.11%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.12
Upside: +60.06%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $20.31
Upside: -21.22%